Human Molecular Genetics Advance Access originally published online on September 7, 2006
Human Molecular Genetics 2006 15(20):3012-3023; doi:10.1093/hmg/ddl243
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity
Department of Pathology, Brigham and Women's Hospital, Program in Neuroscience, Harvard Medical School, 77 Avenue Louis Pasteur, New Research Building, Room 652, Boston, MA 02115, USA
* To whom correspondence should be addressed. Tel: +1 6175254405; Fax: +1 6175254422; Email: mel_feany{at}hms.harvard.edu
Received July 19, 2006; Revised August 28, 2006; Accepted September 4, 2006
-synuclein is a neuronal protein implicated genetically in Parkinson's disease.
-synuclein localizes to the nucleus and presynaptic nerve terminals. Here we show that
-synuclein mediates neurotoxicity in the nucleus. Targeting of
-synuclein to the nucleus promotes toxicity, whereas cytoplasmic sequestration is protective in both cell culture and transgenic Drosophila. Toxicity of
-synuclein can be rescued by administration of histone deacetylase inhibitors in both cell culture and transgenic flies.
-synuclein binds directly to histones, reduces the level of acetylated histone H3 in cultured cells and inhibits acetylation in histone acetyltransferase assays.
-synuclein mutations that cause familial Parkinson's disease, A30P and A53T, exhibit increased nuclear targeting in cell culture. These findings implicate nuclear
-synuclein in promoting nigrostriatal degeneration in Parkinson's disease and encourage exploration of histone deacetylase inhibitors as potential therapies for the disorder.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
S. Azeredo da Silveira, B. L. Schneider, C. Cifuentes-Diaz, D. Sage, T. Abbas-Terki, T. Iwatsubo, M. Unser, and P. Aebischer Phosphorylation does not prompt, nor prevent, the formation of {alpha}-synuclein toxic species in a rat model of Parkinson's disease Hum. Mol. Genet., March 1, 2009; 18(5): 872 - 887. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Xun, R. A. Sowell, T. C. Kaufman, and D. E. Clemmer Quantitative Proteomics of a Presymptomatic A53T {alpha}-Synuclein Drosophila Model of Parkinson Disease Mol. Cell. Proteomics, July 1, 2008; 7(7): 1191 - 1203. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Crews, H. Mizuno, P. Desplats, E. Rockenstein, A. Adame, C. Patrick, B. Winner, J. Winkler, and E. Masliah {alpha}-Synuclein Alters Notch-1 Expression and Neurogenesis in Mouse Embryonic Stem Cells and in the Hippocampus of Transgenic Mice J. Neurosci., April 16, 2008; 28(16): 4250 - 4260. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Cao, H.-J. Song, T. Gangi, A. Kelkar, I. Antani, D. Garza, and M. Konsolaki Identification of Novel Genes That Modify Phenotypes Induced by Alzheimer's {beta}-Amyloid Overexpression in Drosophila Genetics, March 1, 2008; 178(3): 1457 - 1471. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. S. Gorbatyuk, S. Li, L. F. Sullivan, W. Chen, G. Kondrikova, F. P. Manfredsson, R. J. Mandel, and N. Muzyczka The phosphorylation state of Ser-129 in human {alpha}-synuclein determines neurodegeneration in a rat model of Parkinson disease PNAS, January 15, 2008; 105(2): 763 - 768. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Gitler, B. J. Bevis, J. Shorter, K. E. Strathearn, S. Hamamichi, L. J. Su, K. A. Caldwell, G. A. Caldwell, J.-C. Rochet, J. M. McCaffery, et al. The Parkinson's disease protein {alpha}-synuclein disrupts cellular Rab homeostasis PNAS, January 8, 2008; 105(1): 145 - 150. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Klein and M. G. Schlossmacher Parkinson disease, 10 years after its genetic revolution: Multiple clues to a complex disorder Neurology, November 27, 2007; 69(22): 2093 - 2104. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. S. Woods, J. M. Boettcher, D. H. Zhou, K. D. Kloepper, K. L. Hartman, D. T. Ladror, Z. Qi, C. M. Rienstra, and J. M. George Conformation-specific Binding of {alpha}-Synuclein to Novel Protein Partners Detected by Phage Display and NMR Spectroscopy J. Biol. Chem., November 23, 2007; 282(47): 34555 - 34567. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Thomas and M. F. Beal Parkinson's disease Hum. Mol. Genet., October 15, 2007; 16(R2): R183 - R194. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. R. Flower, C. Clark-Dixon, C. Metoyer, H. Yang, R. Shi, Z. Zhang, and S. N. Witt YGR198w (YPP1) targets A30P {alpha}-synuclein to the vacuole for degradation J. Cell Biol., July 30, 2007; 177(6): 1091 - 1104. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. F. Outeiro, E. Kontopoulos, S. M. Altmann, I. Kufareva, K. E. Strathearn, A. M. Amore, C. B. Volk, M. M. Maxwell, J.-C. Rochet, P. J. McLean, et al. Sirtuin 2 Inhibitors Rescue {alpha}-Synuclein-Mediated Toxicity in Models of Parkinson's Disease Science, July 27, 2007; 317(5837): 516 - 519. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. L. Schneider, C. R. Seehus, E. E. Capowski, P. Aebischer, S.-C. Zhang, and C. N. Svendsen Over-expression of alpha-synuclein in human neural progenitors leads to specific changes in fate and differentiation Hum. Mol. Genet., March 15, 2007; 16(6): 651 - 666. [Abstract] [Full Text] [PDF] |
||||








